Skip to main content

Calcium pyrophosphate deposition

Pseudogout

Medical Professionals

Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find the Calcium pyrophosphate deposition article more useful, or one of our other health articles.

What is calcium pyrophosphate deposition or pseudogout?12

Previously known as pseudogout, calcium pyrophosphate deposition disease (CPPD) is an inflammation of joints caused by the deposition of calcium pyrophosphate (CPP) crystals in articular and periarticular tissues.

How common is calcium pyrophosphate deposition?(Epidemiology)34

  • Calcium pyrophosphate deposition is common in the elderly. Half of adults develop radiographic changes typical of CPPD by the age of 80.

  • 30-50% of patients with CPPD are over the age of 85.4

  • Most cases of CPPD are non-familial but mutations in the ANK human gene (ANKH) have been demonstrated in some families.5

  • Due to the low sensitivity of conventional radiography, it is likely that the prevalence of CPPD is underestimated.

CPPD is associated with:467

  • Dehydration.

  • Intercurrent illness.

  • Previous surgery or trauma to the joint.

  • A history of gout.

  • Family history of CPPD.

  • Osteoarthritis.

  • Primary hyperparathyroidism.

  • Haemochromatosis.

  • Hypophosphatasia.

  • Hypomagnesaemia.

Calcium pyrophosphate symptoms34

CPPD is often asymptomatic, with only radiographic changes of chondrocalcinosis.

Calcium pyrophosphate deposition may cause an acute or chronic arthritis:

Acute CPP crystal arthritis (or pseudogout):

  • Acute onset of monoarticular or oligoarticular arthritis.

  • The knee is the most commonly involved joint, followed by the wrist.

  • Acute attacks of CPPD disease usually settle within 10 days but may last for weeks or months.

  • Systemic symptoms including fevers, and chills, and constitutional symptoms may occur.

Chronic CPP crystal arthritis:

  • Most affected patients have a polyarticular form of arthritis that resembles osteoarthritis, but with flares of inflammatory signs and symptoms and by unusually severe articular damage. Involvement of joints such as the glenohumeral joint, wrist, and metacarpophalangeal joints, which are not often affected by typical osteoarthritis, should lead one to suspect CPPD disease.

  • A rarer form of polyarticular CPPD disease resembles rheumatoid arthritis, with persistent inflammatory arthritis that affects large and small joints. Flares often involve joints sequentially, and involvement is less symmetric than that seen with rheumatoid arthritis.

Differential diagnosis

Investigations38

  • Plain x-ray, ultrasound, CT scan and DECT scans can all be used in the diagnosis of CPPD.

  • Crystals can be identified on aspiration of the joint fluid.

Calcium pyrophosphate deposition treatment and management8910 11

Unlike gout, there are no specific disease-modifying treatments for the elimination of CPP crystals from the body. Treatment is therefore largely symptomatic, as well as ensuring good management of any underlying metabolic conditions. Care should be tailored to individual patients and should take account of any comorbidities and existing medication regimes.

The European guidelines advice the use of non-steroidal anti-inflammatory drugs (NSAIDs), colchicine and corticosteroids (intra-articular or systemic). The drug of choice will depend on the patient's age and comorbidities.

In 2023, a large study supported the use of prednisolone 30 mg a day as the first line treatment for CPPD. If colchicine is used, initiation in the first 12 hours of symptoms is important.

For chronic CPP crystal arthritis:

  • Daily colchicine is the preferred first-line treatment, whereas methotrexate and tocilizumab are considered second-line options.47

  • For patients with monoarticular or oligoarticular large-joint involvement, repeated intra-articular injections of glucocorticoids may control symptoms.

Prognosis4

  • Acute attacks often resolve within ten days.

  • However some acute attacks may last for weeks or months.

  • Some patients develop progressive joint damage with functional limitation.

  • Chronic CPPD is characterised by recurrent flare-ups, with symptoms that frequently overlap those of rheumatoid arthritis.

  • Prognosis will also be dependent on any underlying cause.

Exclusive updates for healthcare professionals

Stay informed with the latest clinical updates, professional insights, and evidence-based guidance. The Patient Pro newsletter curates essential content for healthcare professionals—delivered straight to your inbox.

Please enter a valid email address

By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.

Further reading and references

  1. Rosenthal AK, Ryan LM; Calcium Pyrophosphate Deposition Disease. N Engl J Med. 2016 Jun 30;374(26):2575-84. doi: 10.1056/NEJMra1511117.
  2. Pseudogout, chondrocalcinosis, CPPD et al: crystal clear… or clear as mud?–The time has come to reconsider the nomenclature of calcium pyrophosphate deposition; S Sirotti et al; Annals of the Rheumatic Diseases
  3. EULAR recommendations for calcium pyrophosphate deposition - Part I: terminology and diagnosis; European League Against Rheumatism (2011)
  4. Azam A, Minalyan A, Naik R; Calcium Pyrophosphate Deposition Disease.
  5. Tsui FW; Genetics and mechanisms of crystal deposition in calcium pyrophosphate deposition disease. Curr Rheumatol Rep. 2012 Apr;14(2):155-60. doi: 10.1007/s11926-011-0230-6.
  6. Calcium pyrophosphate deposition disease: The arthropathy formerly known as “Pseudogout”; BPAC NZ
  7. Calcium pyrophosphate deposition disease; Prof T Pascar et al; The Lancet
  8. Calcium pyrophosphate dihydrate deposition disease; R Sharma; Radiopedia
  9. EULAR recommendations for calcium pyrophosphate deposition - Part II Management; European League Against Rheumatism (2011)
  10. Recent advances in the therapeutic management of calcium pyrophosphate deposition disease; P Voulgari et al; Frontiers in Medicine
  11. Diagnosis and Treatment of Calcium Pyrophosphate Deposition (CPPD) Disease: A Review; S Cowley and G McCarthy; Open Access Rheumatology: Research and Reviews

About the authorView full bio

Author image

Dr Philippa Vincent, MRCGP

General Practitioner, Medical Author

MB BS, Bsc, MRCGP (2000), DCH, DFSRH, DRCOG

Dr Philippa Vincent is an NHS GP working in North London.

About the reviewerView full bio

Author image

Dr Toni Hazell, FRCGP

MBBS, BSc, FRCGP, DFSRH, Dip GU med, DRCOG, DCH (London, UK, 2000)

Dr. Toni Hazell qualified from St. Mary’s Hospital Medical School and did her VTS at Northwick Park Hospital.

Article history

The information on this page is written and peer reviewed by qualified clinicians.

flu eligibility checker

Ask, share, connect.

Browse discussions, ask questions, and share experiences across hundreds of health topics.

symptom checker

Feeling unwell?

Assess your symptoms online for free